Scopus BioPharma Inc.

À propos de la société

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. Scopus BioPharma Inc. was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is based in New York, New York.

Secteur

Healthcare

Activité

Biotechnology

Place de cotation

OTCMKTS

Source des informations de marché · Oct 5, 2026

Identité selon la SEC · Oct 5, 2026